116 related articles for article (PubMed ID: 10672934)
1. Development of new adherent mutant from human myeloma-derived cell line: in vitro model of anaplastic transformation of myeloma.
Jung KC; Park CS; Sohn HW; Kook MC; Chung DH; Choi YK; Hyun BH; Lee IS; Bae YM; Song HG; Park SH
Mol Cells; 1999 Dec; 9(6):657-61. PubMed ID: 10672934
[TBL] [Abstract][Full Text] [Related]
2. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype.
Bellamy WT; Mendibles P; Bontje P; Thompson F; Richter L; Weinstein RS; Grogan TM
Cancer Chemother Pharmacol; 1996; 37(4):305-16. PubMed ID: 8548875
[TBL] [Abstract][Full Text] [Related]
3. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
[TBL] [Abstract][Full Text] [Related]
4. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
Tsunenari T; Koishihara Y; Nakamura A; Moriya M; Ohkawa H; Goto H; Shimazaki C; Nakagawa M; Ohsugi Y; Kishimoto T; Akamatsu K
Blood; 1997 Sep; 90(6):2437-44. PubMed ID: 9310495
[TBL] [Abstract][Full Text] [Related]
5. Mutations in mouse myeloma cells: implications for human multiple myeloma and the production of immunoglobulins.
Weitzman S; Margulies DH; Scharff MD
Ann Intern Med; 1976 Jul; 85(1):110-6. PubMed ID: 820230
[TBL] [Abstract][Full Text] [Related]
6. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
7. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
8. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
9. ALK-transformed mature T lymphocytes restore early thymus progenitor features.
Congras A; Hoareau-Aveilla C; Caillet N; Tosolini M; Villarese P; Cieslak A; Rodriguez L; Asnafi V; Macintyre E; Egger G; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2020 Dec; 130(12):6395-6408. PubMed ID: 33141118
[TBL] [Abstract][Full Text] [Related]
10. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
Uchiyama H; Barut BA; Mohrbacher AF; Chauhan D; Anderson KC
Blood; 1993 Dec; 82(12):3712-20. PubMed ID: 8260708
[TBL] [Abstract][Full Text] [Related]
11. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B.
Yam JW; Chan KW; Hsiao WL
Oncogene; 2001 Jan; 20(1):58-68. PubMed ID: 11244504
[TBL] [Abstract][Full Text] [Related]
13. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice.
Barton BE; Cullison J; Jackson J; Murphy T
Proc Soc Exp Biol Med; 2000 Feb; 223(2):190-7. PubMed ID: 10654623
[TBL] [Abstract][Full Text] [Related]
14. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin.
Matsuo Y; Drexler HG; Harashima A; Okochi A; Hasegawa A; Kojima K; Orita K
Leuk Res; 2004 Aug; 28(8):869-77. PubMed ID: 15203285
[TBL] [Abstract][Full Text] [Related]
15. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
17. [The mechanisms of myeloma cell growth].
Shimizu S
Nihon Rinsho; 1995 Mar; 53(3):557-63. PubMed ID: 7699885
[TBL] [Abstract][Full Text] [Related]
18. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
